Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319968 | 1.00 | KMT2A (0.38) | KMT2AMEN1ALDH1A1FKBP1ATOP2A | |
| SCHEMBL28714852 | 0.86 | FKBP1A (0.32) | FKBP1ATOP2A | |
| SCHEMBL19733021 | 0.86 | FKBP1A (0.32) | FKBP1ATOP2A | |
| SCHEMBL15320022 | 0.86 | KMT2A (0.37) | KMT2AMEN1ALDH1A1FKBP1ATOP2A | |
| SCHEMBL15320018 | 0.86 | KMT2A (0.37) | KMT2AMEN1ALDH1A1FKBP1ATOP2A | |
| SCHEMBL15319566 | 0.85 | KMT2A (0.36) | KMT2AMEN1ALDH1A1FKBP1ATOP2A | |
| SCHEMBL15319869 | 0.85 | KMT2A (0.36) | KMT2AMEN1ALDH1A1FKBP1ATOP2A | |
| SCHEMBL15319563 | 0.85 | KMT2A (0.36) | KMT2AMEN1ALDH1A1FKBP1ATOP2A | |
| SCHEMBL15318882 | 0.85 | KMT2A (0.36) | KMT2AMEN1ALDH1A1FKBP1ATOP2A | |
| SCHEMBL15318883 | 0.85 | KMT2A (0.36) | KMT2AMEN1ALDH1A1FKBP1ATOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| EP-3512851-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | Entasis Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| EP-2834239-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | Astrazeneca AB (SE) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, MRPL21 | KMT2A 1573/4885MEN1 2404/4885ALDH1A1 214/4885 |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, SI | KMT2A 1304/4885MEN1 3098/4885ALDH1A1 319/4885 |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | LCT, MGAM, MRPL21 | KMT2A 1573/4885MEN1 2404/4885ALDH1A1 214/4885 |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | LCT, MGAM, SI | KMT2A 1304/4885MEN1 3098/4885ALDH1A1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.